Learn More
BACKGROUND/AIM Minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) before allogeneic hematopoietic stem cell transplantation (alloHSCT) can influence the results of therapy.(More)
Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe(More)
BACKGROUNDS Granulopoesis colony-stimulating factor filgrastim is used to mobilize peripheral stem cells but there are concerns regarding an elevated risk of haematological malignancies. We analyzed(More)
G-CSF filgrastim is frequently used to mobilise CD34þ cells in donors before PBSC collection. Several observational reports raised concerns regarding an elevated risk of haematological malignancies(More)